Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: pharmathene inc

Md. pharma prevails against rival in Delaware’s highest court

PharmAthene Inc., an Annapolis pharmaceutical company, recently scored a victory in Delaware’s highest court in a dispute with rival Siga Technologies Inc. The Delaware Supreme Court affirmed the Delaware Court of Chancery’s decision to award PharmAthene lump sum expectation damages ...

Read More »

PharmAthene changes CEO, reduces staff

PharmAthene Inc., an Annapolis-based company that develops biodefense products, is changing its chief executive officer and plans to cut its 11-person staff by two-thirds, the firm announced this week. John M. Gill, a director of PharmAthene for nine years, will ...

Read More »

PharmAthene awarded $113M in drug dispute

(Bloomberg) Siga Technologies Inc., the maker of a smallpox drug to counter biological attacks, was told to pay $113 million to Annapolis-based PharmAthene Inc. in a dispute over the medicine that drove Siga to seek bankruptcy protection last year. PharmAthene ...

Read More »

Annapolis-based PharmAthene cancels planned merger

PharmAthene Inc., an Annapolis-based biodefense company developing medical countermeasures against biological and chemical threats, announced Monday it has called off its planned merger with Seattle-based Theraclone Sciences Inc., a privately held developer of targeted antibody drugs.

Read More »

PharmAthene gets FDA nod on SparVax

PharmAthene Inc., of Annapolis, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Food and Drug Administration has lifted a nearly-10-month hold placed on a proposed Phase II study of SparVax, allowing a clinical trial of the next-generation anthrax vaccine to proceed.

Read More »

Tough medicine: Court rules firm may get $100M

Annapolis-based PharmAthene Inc. may be entitled to at least $100 million in damages after the Delaware Supreme Court held that Siga Technologies Inc. acted in bad faith in backing out of a proposed licensing agreement for its smallpox treatment medication to be used in response to a biochemical attack.

Read More »

PharmAthene nerve agent blocker tested

PharmAthene Inc., of Annapolis, a biodefense company developing medical countermeasures against biological and chemical threats, announced that the U.S. Army Medical Research Institute for Chemical Defense has completed initial in vitro testing of the company's recombinant butyrylcholinesterase (rBChE) bioscavenger.

Read More »

PharmAthene reports increased loss

PharmAthene Inc., of Annapolis, which is developing medical countermeasures to chemical and biological warfare agents, saw its net loss grow despite an increase in revenue during the 12-month period of 2012, compared to the prior year. PharmAthene reported a net ...

Read More »

Annapolis-based PharmAthene gets $5.7M DoD contract

ANNAPOLIS — PharmAthene Inc. of Annapolis, a company developing medical defenses against biological and chemical threats, said it has been awarded a $5.7 million, 18-month contract by the U.S. Department of Defense to continue development of a counter-measure to ward ...

Read More »